Calidi Biotherapeutics, Inc.

CLDI NYSE CIK: 0001855485

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 4475 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121
Mailing Address 4475 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121
Phone 858-794-9600
Fiscal Year End 1231
EIN 862967193

Financial Overview

FY2025

$14.18M
Total Assets
$12.21M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 2, 2026 View on SEC
SCHEDULE 13D Beneficial ownership report (>5%) March 31, 2026 View on SEC
8-K Current report of material events March 27, 2026 View on SEC
10-K Annual financial report March 27, 2026 View on SEC
8-K Current report of material events March 11, 2026 View on SEC
424B5 Prospectus supplement March 9, 2026 View on SEC
SCHEDULE 13D Beneficial ownership report (>5%) March 9, 2026 View on SEC
424B5 Prospectus supplement March 6, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 10, 2026 View on SEC
8-K Current report of material events February 10, 2026 View on SEC

Annual Reports

10-K March 27, 2026
  • Advancing Phase 1 clinical trial for CLD-101 brain cancer treatment
  • Successfully completed merger with First Light Acquisition Group to secure capital
View Analysis

Insider Trading

SELL 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.